Total synthesis of (±) - pentenomycin

A concise stereoselective route to (±)-pentenomycin 1 in 33% overall yield starting from the readily accessible Diels-Alder adduct 4 is reported. The key reaction involves decarbonylation of β-methoxy-α,β-unsaturated aldehyde 8 obtained from β-hydroxy-dimethylketal 6

A formal total synthesis of (±) - neplanocin A

Stereoselective formal synthesis of (±)-neplanocin A from a cyclopentane derivative employing an elegant strategy involving reiterative usage of an already existing acetonide protecting group is reported. The acetonide protecting group that is carried forward intact right from the starting adduct to an advanced intermediate is shuffled around twice as in a "relay race" through the synthetic sequence, thus avoiding unnecessary employment of additional protecting groups

Synthesis of a novel, bowl-like bis γ-lactone

Synthesis of a compound with bowl-like, symmetrical molecular architecture, starting from a Diels-Alder adduct 7, derived from a reaction between 2,5-dihydro-2,5-dimethoxyfuran and 1,2,3,4-tetrachloro-5,5-dimethoxycyclopentadiene, is reported

Authorizing Multiple Chemical Passwords by a Combinatorial Molecular Keypad Lock

A combinatorial fluorescent molecular sensor operates as a highly efficient molecular security system. The ability of a pattern-generating molecule to process diverse sets of chemical inputs, discriminate among their concentrations, and form multivalent and kinetically stable complexes is demonstrated as a powerful tool for processing a wide range of chemical “passwords” of different lengths. This system thus indicates the potential for obtaining unbreakable combination locks at the molecular scale

Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy

A strategy combining covalent conjugation of photosensitizers to a peptide ligand directed to the melanocortin 1 (MC1) receptor with the application of sequential LED light dosage at near-IR wavelengths was developed to achieve specific cytotoxicity to melanocytes and melanoma (MEL) with minimal collateral damage to surrounding cells such as keratinocytes (KER). The specific killing of melanotic cells by targeted photodynamic therapy (PDT) described in this study holds promise as a potentially effective adjuvant therapeutic method to control benign skin hyperpigmentation or superficial melanotic malignancy such as Lentigo Maligna Melanoma (LMM).ISSN:2045-232

Chemical characterization of Endomorphine-TAMRA conjugates.

<p><b>(A)</b> Chemical structure of EM-TAMRA indicated by modified Endomorphine-1 peptide in blue and TAMRA-Maleimide in magenta. Absorbance and Emission spectra of <b>(B)</b> 200 μM TAMRA-Maleimide and <b>(C)</b> 20 μM EM-TAMRA at pH 7.24. <b>(D)</b> Absorbance of 20 μM EM-TAMRA at different pH 2.15–10. I_Normalized = Normalized intensity; I_abs = Normalized absorbance.</p

Investigating endogenous µ-opioid receptors in human keratinocytes as pharmacological targets using novel fluorescent ligand

<div><p>Opioids in skin function during stress response, regeneration, ageing and, particularly in regulating sensation. In chronic pruritus, topical treatment with Naltrexone changes μ-opioid receptor (μ-OR) localization to relieve itch. The molecular mechanisms behind the effects of Naltrexone on μ-OR function in reduction of itching behavior has not been studied. There is an immediate need to understand the endogenous complexity of μ-OR dynamics in normal and pathological skin conditions. Here we evaluate real-time behavior of μ-OR-Endomorphine complexes in the presence of agonist and antagonists. The μ-OR ligand Endomorphine-1 (EM) was conjugated to the fluorescent dye Tetramethylrhodamine (TAMRA) to investigate the effects of agonist and antagonists in N/TERT-1 keratinocytes. The cellular localization of the EM-TAMRA was followed through time resolved confocal microscopy and population analysis was performed by flow cytometry. The <i>in vitro</i> analyses demonstrate fast internalization and trafficking of the endogenous EM-TAMRA-μ-OR interactions in a qualitative manner. Competition with Endomorphine-1, Naltrexone and CTOP show both canonical and non-canonical effects in basal and differentiated keratinocytes. Acute and chronic treatment with Naltrexone and Endomorphine-1 increases EM-TAMRA binding to skin cells. Although Naltrexone is clinically effective in relieving itch, the mechanisms behind re-distribution of μ-ORs during clinical treatments are not known. Our study has given insight into cellular mechanisms of μ-OR ligand-receptor interactions after opioid agonist and antagonist treatments <i>in vitro</i>. These findings potentially offer opportunities in using novel treatment strategies for skin and peripheral sensory disorders.</p></div

Competition with μ-OR ligands shows specificity of EM-TAMRA binding and differences between basal and differentiated keratinocyte populations.

<p>(A) For live cell imaging, cells were pre-incubated with 10 μM competitor for five min before addition of EM-TAMRA (200 nM) in the presence of 10 μM competitor at 37°C. As compared to the control, Endomorphine-1 was more effective in competing for membrane binding with EM-TAMRA than CTOP and Naltrexone in basal N/TERT-1 cells. Scale bar represents 10 μm. (B) Flow cytometry analysis after 30 min pre-treatment with ligands on ice show significant reduction in EM-TAMRA positive populations during competition with Endomorphine-1 at low (100 nM) as well as high (10 μM) concentrations in both basal and differentiated keratinocytes. (C) CTOP (100 nM and 1 μM) was able to block EM-TAMRA binding in basal N/TERT-1 but not in differentiated cells. (D) Naltrexone shows competition at higher concentrations of 1 μM to 10 μM but not at low concentration of 100 nM. Data are represented as mean ± SD from four replicate experiments (N = 4) and were subjected to ordinary One-way ANOVA using Dunnett’s multiple comparison <i>post hoc</i> test. * P < 0.05; ** P < 0.01; *** P < 0.001. EM = Endomorphine-1; NTX = Naltrexone.</p

Acute and chronic exposure of keratinocytes to opioid antagonist Naltrexone and agonist Endomorphine-1 affect cell membrane localization of μ-OR and enhances binding of EM-TAMRA.

<p>(A) Live cell imaging shows reduced binding of EM-TAMRA (grey) in two day Endomorphine-1 and Endomorphie-1 + Naltrexone double pre-treated cells. Subtle differences are observed in Naltrexone treated cells. Scale bar represents 10μm. (B) In chronic, five day pre-treated cells a clear reduction of EM-TAMRA binding is observed in Endomorphine-1 and Naltrexone treated cells. The double treatment with Endomorphine-1 and Naltrexone results in increased binding of EM-TAMRA to keratinocytes. Scale bar represents 10 μm. (C) Flow cytometry analyses reveal reduction of EM-TAMRA binding in Endomorphine-1 and Naltrexone + Endomorphine-1 double treated basal cells after two day incubation similar to live cell imaging data from basal cells. In differentiated keratinocytes all treatments led to a reduction of EM-TAMRA positive populations. Only Endomorphine-1 and Naltrexone individual treatments display statistically significant reductions. (D) Chronic treatment with Naltrexone + Endomorphine-1 combination results in increased binding of EM-TAMRA in basal keratinocytes. In differentiated cells single compound treatment reduces EM-TAMRA positive populations but the double treatment with Naltrexone + Endomorphine-1 increases binding. Data are represented as mean ± SD from four replicate experiments (N = 4) and were subjected to ordinary One-way ANOVA using Dunnett’s multiple comparison <i>post hoc</i> test. * P < 0.05; ** P < 0.01; *** P < 0.001. WGA = Wheat germ agglutinin, EM = Endomorphine-1; NTX = Naltrexone.</p

HPLC parameters.

<p>HPLC parameters.</p